How we got here

From launching in June 2020 to our planned open consultation in July 2021, GCTC's journey is detailed below..

June 2020

The GCTC launched to produce reliable and proportionate Guidance for RCTs in all health interventions.

Jan - Mar 2021

Guidance development of the first draft. Quicksand, a design-thinking and innovation practice based in India, began consultations with RCT teams and participants in India, South Africa, Nigeria, Thailand, Brazil, Sierra Leone and Kenya to gather insights from diverse RCT types and settings.

July 2021

Final draft published for open consultation

October - November 2021

Review of consultation responses and redrafting guidance

May 2022

The Collaborative published revised draft guidance

June -July 2020

We ran a global survey to hear from researchers whose trials had been impacted by the Covid-19 pandemic to capture the innovative practices that have enabled some trials to continue and the challenges that have affected others.

April 2021

Further consultation with multidisciplinary stakeholders and programme of participant/public focused workshops.

August 2021

Produced the report on Conducting Clinical Trials During a Pandemic: Reviewing the resilience of the ecosystem for Randomized Controlled Trials (RCTs). This report was based on the global survey of researchers experiences, we ran in 2020.

December 2021

Workshops with multidisciplinary writing group of global experts scrutinised Collaborative's response to consultation feedback

Sep -Dec 2020

We consulted our Steering Group and over 80 experts through a series of workshops focusing on the writing process and Guidance document content.

May -June 2021

Guidance development of the second draft. Quicksand completed its consultations and produced a report with findings and recommendations for the guidance.

August - September 2021

Launch of public consultation

 

Translation of draft guidance into Arabic, simplified Chinese, Japanese, Spanish, French

March 2022

The Collaborative secures continued funding from Wellcome and the Gates Foundation. Moves to new not-for-profit host, Protas.